# Summerway Capital

Summerway Capital is an Asset Manager based in London, United Kingdom.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** London, United Kingdom
- **Assets under management:** Undisclosed
- **Website:** celadonpharma.com
- **LinkedIn:** linkedin.com/company/summerway-capital

## Regulatory record

- **Reports private funds:** No

## About

Summerway Capital Plc is a London-based investment company that employs a Buyout strategy. It is headquartered in the UK. The firm has one staff member.

## Sectors

- Healthcare Services

## Questions

### What regulatory permissions does Celadon hold that are structurally significant?

Celadon holds a Home Office license to cultivate high-THC cannabis for medicinal purposes, one of a very limited number issued in the UK. The license imposes strict security, quality, and compliance requirements, creating a barrier to entry that new entrants cannot easily clear. Additionally, the company's manufacturing facility operates to Good Manufacturing Practice standards required for pharmaceutical production.

### How does Celadon generate revenue?

Revenue comes from two channels. The primary domestic channel is the supply of unlicensed cannabis-based medicinal products to UK patients via private prescriptions written by specialist doctors. The secondary channel, activated in early 2024 following a commercial export announcement, involves wholesale supply of pharmaceutical-grade cannabis flower to distributors in continental Europe. Revenue remains early-stage; the company reported approximately £200,000 for 2023.

### What investment stages or deal types did Summerway originally target before the Celadon transaction?

According to its original AIM admission documents, Summerway was formed as a special-purpose acquisition company targeting controlling stakes in European small-cap companies, with a generalist buyout mandate. Prior to the Celadon reverse takeover, no completed platform acquisitions were publicly disclosed. The vehicle's pre-Celadon deployment record is effectively nil.

### Who makes investment and operational decisions at the combined entity?

Operational and strategic decisions now sit with the Celadon Pharmaceuticals board and management team rather than a Summerway investment committee. The key operators are the executives running the cultivation facility, quality systems, and commercial partnerships. Because the firm is a single-asset operating company listed on AIM, material decisions are subject to board approval and, in certain cases, shareholder consent under AIM rules.

## Related profiles

- [Summer Street Capital Partners](https://altss.com/profile/summer-street-capital-partners)
- [SUMMIT Africa](https://altss.com/profile/summit-africa)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/summerway-capital-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology